(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2(Date:10/7/2008)...Colo., Oct. 7 /- A study published in... stem cell self-renewal,reported that InVitria,s ...,human serum albumin) was an effective replacement... article entitled, "The ground state of embryonic ...s used Cellastim as a recombinant,albumin in place...
(Date:10/7/2008)...s., Oct. 7 /- Taligen Therapeutics In... the Company,s pipeline,candidates were presented ...asel, Switzerland. The data highlighted the candid...ent-mediated diseases., "These highlighted presen...nted at the conference, reveal the deep expertise ...
(Date:10/7/2008)...cts highlighting CIMZIA,s long-term benefits and v...s presented at American College,of Gastroenterolog...ll/ -- Data from two studies,presented this week b...(ACG) Annual Meeting demonstrate that CIMZIA(R) (c...lpha (Tumor Necrosis Factor alpha) - provides,sust...
(Date:10/7/2008).... 7 /- Ardea Biosciences, I... entitled "RDEA119, a Potent,and Highly Selective ...Sodium (DSS) -- induced Chronic Colitis in Mice," ...erology (ACG) 2008 Annual Meeting in Orlando,Flor...nical study of,RDEA119, the Company,s lead mitogen...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Entrust Expands Relationship with Slovenia Implements Second generation ePassport Solution 4798 1Entrust Expands Relationship with Slovenia Implements Second generation ePassport Solution 4798 2Entrust Expands Relationship with Slovenia Implements Second generation ePassport Solution 4798 3Entrust Expands Relationship with Slovenia Implements Second generation ePassport Solution 4798 4Entrust Expands Relationship with Slovenia Implements Second generation ePassport Solution 4798 5Miami HIV Clinic Administrator Pleads Guilty for Role in a 2414 Million Medicare Fraud Scheme 26230 1Miami HIV Clinic Administrator Pleads Guilty for Role in a 2414 Million Medicare Fraud Scheme 26230 2Gulf Coast Dialysis Caregivers Volunteers Brace for Hurricane Ike 3B Prepare to Maintain Power Continued Access for Patients to Life Saving Treatmen 26226 1Gulf Coast Dialysis Caregivers Volunteers Brace for Hurricane Ike 3B Prepare to Maintain Power Continued Access for Patients to Life Saving Treatmen 26226 2Arius announces leading independent proxy firm RiskMetrics ISS Canada recommends shareholders vote for the arrangement involving its acquisition by 7587 1Arius announces leading independent proxy firm RiskMetrics ISS Canada recommends shareholders vote for the arrangement involving its acquisition by 7587 2Arius announces leading independent proxy firm RiskMetrics ISS Canada recommends shareholders vote for the arrangement involving its acquisition by 7587 3... 2007 - Biogen Idec (NASDAQ: BIIB),and Elan Corpor...ta,from the TOUCH Prescribing Program(TM) and TYGR...evious clinical studies of,TYSABRI(R) (natalizumab...e American Academy of Neurology in Boston, MA were... a sustained treatment,effect on clinical relapses...
...-May 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today ann...or-sponsored study of the company,s drug, IPLEX(TM...M1)., Preliminary results of the clinical study, b...ol of Medicine and Dentistry,showed that six mont...day in six patients met the primary study endpoint...
Other Medicine Technology:Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 2Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 4Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 5Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 6Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4Phaco chopper 1 mm fully cutting edge.
Round handle dull finish. For right handed surgeon.
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm.
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand.
Medicine Products: